Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
(Source: OncoTargets and Therapy)
Source: OncoTargets and Therapy - June 20, 2023 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Therapeutic Effect of Polaprezinc on Reflux Esophagitis in the Rat Model
ConclusionsPolaprezinc has a significant therapeutic effect on RE in rats, which can reduce the levels of IL-8 and PGE2 and downregulate the expression of PI3K/Akt/mTOR signal pathway protein. The efficacy of polaprezinc in the treatment of reflux esophagitis is comparable to that of PPI, and the combination of them is more effective in the reflux esophagitis treatment. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - June 19, 2023 Category: Gastroenterology Source Type: research
